Atea Pharmaceuticals Completes Enrollment in Phase 3 Hepatitis C Trial with Novel Drug Combination
核心洞察
Atea Pharmaceuticals has completed enrollment of more than 880 treatment-naïve patients in its C-BEYOND Phase 3 trial evaluating bemnifosbuvir and ruzasvir for hepatitis C treatment.
The trial represents the first global Phase 3 head-to-head comparison of direct-acting antivirals, with topline results expected mid-2026.
The investigational regimen offers potential advantages including shorter treatment duration and reduced drug-drug interaction risk compared to current standard of care.
Atea Pharmaceuticals has completed patient enrollment in its pivotal Phase 3 trial evaluating a novel fixed-dose combination regimen for hepatitis C virus (搜索) (HCV) treatment, marking a significant milestone in the company's efforts to develop what it describes as a best-in-class therapy for this persistent global health challenge.
The C-BEYOND trial enrolled more than 880 treatment-naïve patients across approximately 120 clinical sites in the United States and Canada to compare the fixed-dose combination of bemnifosbuvir and ruzasvir against the established regimen of sofosbuvir and velpatasvir. Topline results from this head-to-head comparison are expected mid-2026.
First Global Head-to-Head DAA Comparison
C-BEYOND represents the first global Phase 3 head-to-head trial of direct-acting antivirals for HCV treatment, according to Atea. The company is simultaneously advancing C-FORWARD, a companion Phase 3 trial evaluating the same drug combination in 880 patients at approximately 120 sites across up to 17 countries outside North America. Enrollment completion for C-FORWARD is expected mid-2026, with topline results anticipated by year-end 2026.
"Completing enrollment in C-BEYOND marks a critical inflection point in our Phase 3 HCV program and we are on track to deliver topline results from this trial mid-2026," said Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea. "Our goal is and has always been to develop a best-in-class HCV treatment that meaningfully advances the standard of care."
Potential Treatment Advantages
The investigational regimen combines bemnifosbuvir, a nucleotide analog polymerase (搜索) inhibitor, with ruzasvir, an NS5A (搜索) inhibitor. The combination is administered orally once-daily for eight weeks in patients without cirrhosis (搜索) or 12 weeks in patients with compensated cirrhosis, compared to the 12-week duration required for all patients receiving the comparator regimen of sofosbuvir and velpatasvir.
Sommadossi highlighted the regimen's target profile, which features "short treatment duration, low risk of drug-drug interactions and convenience with no food effect," positioning it to "address the evolving needs of today's patients and bring us closer to the ultimate goal of HCV eradication."
Addressing Persistent Treatment Challenges
Despite the availability of direct-acting antivirals, HCV remains a significant global health burden. Up to 4 million people in the US are living with chronic HCV (搜索), while an estimated 50 million people are infected worldwide with approximately one million new infections occurring annually.
In the United States, HCV diagnoses continue to outpace annual cure rates, creating an ongoing treatment gap. According to healthcare providers treating HCV patients, approximately 80 percent of patients take multiple medications to manage comorbidities and coinfections. Concerns related to drug-drug interactions with currently approved HCV therapeutics represent a significant factor in treatment delays.
Trial Design and Endpoints
Both Phase 3 trials are open-label studies enrolling treatment-naïve patients, including those with or without compensated cirrhosis (搜索). The primary endpoint for each trial is HCV RNA below the lower limit of quantitation at 24 weeks from treatment start, encompassing sustained virologic response 12 weeks post-treatment (SVR12) in each arm. The 24-week measurement timepoint ensures the primary endpoint occurs at the same relative time from treatment initiation across all patients.
The trials' design reflects the clinical reality that less than 10 percent of HCV-infected patients in the US have cirrhosis (搜索), with infections predominantly affecting patients aged 20-49 years. Chronic HCV (搜索) infection remains the leading cause of liver cancer (搜索) in the US, Europe, and Japan, with approximately 240,000 deaths occurring globally each year.